SANDOSTATIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SANDOSTATIN (SANDOSTATIN).
Synthetic octapeptide analog of somatostatin with longer half-life. Inhibits growth hormone (GH), glucagon, and insulin secretion. Reduces splanchnic blood flow and suppresses serotonin release from neuroendocrine tumors.
| Metabolism | Metabolized by peptidases; not extensively hepatic; 32% excreted unchanged in urine; metabolites inactive; half-life ~1.7 hours. |
| Excretion | Renal: ~32% unchanged; biliary/fecal: ~66% as metabolites; total clearance ~160 mL/min. |
| Half-life | Terminal elimination half-life: 1.7–1.9 hours (subcutaneous); prolonged in hepatic impairment (up to 2.6 h). After intravenous bolus, biphasic elimination with t½ α ~0.2 h and t½ β ~1.5 h. |
| Protein binding | ~65% bound primarily to alpha-1 acid glycoprotein and, to a lesser extent, albumin. |
| Volume of Distribution | Apparent Vd: 0.2–0.4 L/kg (total, ~30 L). Indicates distribution mainly into extracellular fluid with limited tissue binding. |
| Bioavailability | Subcutaneous: ~100% (almost complete); intramuscular (long-acting): slow release with absolute bioavailability ~50% of total dose delivered over 4 weeks; intravenous: 100%. |
| Onset of Action | Subcutaneous: acromegaly symptom improvement and GH suppression within 1–2 hours; intravenous: immediate; intramuscular (long-acting depot): reaches therapeutic levels after 2–3 weeks. |
| Duration of Action | Subcutaneous: GH suppression lasts 6–8 hours; intravenous: 4–6 hours; intramuscular (depot): 4 weeks (for acromegaly, repeat injection every 4 weeks). |
| Molecular Weight | 1019.3 |
Subcutaneous: 50-100 mcg every 8-12 hours. Intravenous bolus: 50 mcg, then continuous infusion 25-100 mcg/hour for acute variceal bleeding.
| Dosage form | INJECTABLE |
| Renal impairment | No adjustment required for mild to moderate impairment. For severe renal impairment (GFR < 30 mL/min), reduce dose by 50% and monitor for toxicity. |
| Liver impairment | No specific Child-Pugh based guidelines. Caution in severe hepatic impairment; monitor liver function and adjust dose based on response. |
| Pediatric use | 0.5-1 mcg/kg subcutaneously every 8-12 hours. Maximum 50 mcg per dose. For continuous IV infusion, 0.5-1 mcg/kg/hour. |
| Geriatric use | No specific dose adjustment required. Use lower end of dosing range due to potential age-related renal impairment and increased sensitivity. |
| 1st trimester | Insufficient human data; animal studies show no fetal harm at clinical doses. Use only if clearly needed. |
| 2nd trimester | Limited human data; no known teratogenicity; monitor fetal growth due to potential GH/IGF-1 suppression. |
| 3rd trimester | Limited human data; risk of fetal growth restriction due to GH/IGF-1 suppression; use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for SANDOSTATIN (SANDOSTATIN).
| Placental transfer | Crosses placenta in animals; human data limited but expected due to low molecular weight. |
| Breastfeeding | Excreted in human milk in small amounts; due to potential for growth suppression in the infant, caution is advised. Alternative agents may be preferred. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to octreotide or any component of the formulation
| Precautions | Gallbladder abnormalities (biliary sludge, cholelithiasis) due to inhibition of gallbladder contraction and bile secretion, Hyperglycemia or hypoglycemia due to altered glucose metabolism, Bradycardia, conduction abnormalities (monitor ECG), Hypothyroidism (suppression of TSH), Intestinal obstruction (rare, due to mesenteric fibrosis in carcinoid patients) |
| Food/Dietary | No significant food interactions. Avoid alcohol due to risk of hypoglycemia and increased vasodilation. Take with food if GI upset occurs. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. Use only if clearly needed. Risks in first trimester: unlikely but unknown. Second/third trimester: potential for fetal growth restriction due to maternal vasoconstriction, though not reported. Advise caution. |
| Fetal Monitoring | Monitor maternal blood glucose, thyroid function, and gallstone formation. Fetal ultrasound for growth and anatomy if used during pregnancy. |
| Fertility Effects | No known adverse effects on fertility. May improve fertility in acromegalic women by reducing GH/IGF-1 levels. No impairment observed in animal studies. |
| Somatostatin analog; use subcutaneous test dose to assess for paradoxical hormone release in acromegaly and neuroendocrine tumors. Monitor for gallstones due to inhibition of gallbladder contraction. Correct hypoglycemia or hyperglycemia before therapy. May reduce severity of esophageal variceal bleeding; use continuous IV infusion in acute settings. Adjust dose in renal impairment: reduce loading dose by 50% if CrCl < 50 mL/min. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly without consulting your doctor. · Report persistent nausea, vomiting, or abdominal pain immediately. · Monitor blood glucose regularly if diabetic; sandostatin may cause hypo- or hyperglycemia. · Avoid alcohol to reduce risk of hypoglycemia and vasodilation. · Inform doctor before surgery or dental procedures. · Do not drive or operate heavy machinery if dizzy or drowsy. |